CAS: 33670-32-5; (Methoxymethyl)Triphenylphosphonium Bromide

该化合物是一种多用途磷盐,广泛用于有机合成,特别是在形成甲基甲基乙醚和氟化二苯醚的中间反应中,其主要优点包括作为甲基添加剂的高度活性,在温和条件下能够进行高效的Wittig脱硫.该化合物具有极强的稳定性和处理性,适合受控反应.该化合物在保护群体化学方面特别有用,因为需要选择性地对氢氧基组进行MOM保护.溴反离子会提高极地溶剂的溶性,有利于同质反应条件.该试剂有利于其在复杂的合成路线上(包括天然产品合成和制药中间体)的可靠性.

结构式图片

欧盟法规

C&L通报

上下游产品

bromethyl methyl ether triphenylphosphine -cyclopropan-cyclopropan -cyclobutan-cyclobutan 3-[1-Methoxy-meth-(Z)-ylidene]-1-methyl-cyclohexanecarbonitrile (E)-1-(Phenylsulfonyl)-3-(β-methoxyvinyl)indole

合成工艺路线路线简述

    溴甲基甲基醚,三苯基膦 以 苯 用作溶剂,化学反应 24.0H,以87.7%的收率获得(甲氧基甲基)三苯基溴化膦
    参考文献:The Preparation And13C-NMR Spectra Of Alkoxymethyltriphenylphosphonium Salts
    标题:The Preparation And13C-NMR Spectra Of Alkoxymethyltriphenylphosphonium Salts
    摘要:烷氧基甲基三苯基膦盐[(C6H5)3Pch2Or]X,X:X:Cl,Br 和 I,R:Ch3,C2H5 和 I-C3H7,由三苯基膦和相应的烷基卤代甲基醚反应得到.在这些盐的 13C-NMR 光谱中,耦合常数(jcp)为 68-71 Hz,大于[(C6H5)3Pch2R]Br(r:H,Ch3 和 I-C3H7),Me3P=s 和 Me3P=se 的耦合常数(jcp:48-56 Hz),而接近 Me3P=o 和 Et3P=o 的耦合常数(66-69 Hz).这些盐的耦合常数(jcp)可能是由盐中的氧原子引起的.
    Doi:10.1246/bcsj.53.3436

    海关参考信息

    专利信息


    专利号:US-9464021-B2
    优先权日:2013-11-01
    标题 :Method of preparation of stereospecific quinone derivatives
    发明人:MEHTA DILIP S; MOHAN PRIYA; SHASTRI MAYANK; REID TED
    权利人:MEHTA DILIP S; MOHAN PRIYA; SHASTRI MAYANK; REID TED
    摘要:The description provides processes for the regio and stereospecific synthesis of polyprenylatedquinone derivatives, such as Vitamin K1, K2 and Ubiquinone, exploiting dithioacetals, especially 1,3-dithiane, mediated Umpolung chemistry which works along a new concept “Inhibiting resonance delocalization (IRD)†to overcome isomerization generated due to delocalization of allyliccarbanion on the Ï€-electron cloud of an allylic systems by the conventional synthesis.

    专利号:US-8853228-B2
    优先权日:2007-06-04
    标 题:Heterocyclic analogs of propargyl-linked inhibitors of dihydrofolate reductase
    发明人:ANDERSON AMY C; WRIGHT DENNIS L; FREY KATHLEEN MARY; PAULSEN JANET LEIGH; SCOCCHERA ERIC WILLIAM; VISWANATHAN KISHORE
    权利人:ANDERSON AMY C; WRIGHT DENNIS L; FREY KATHLEEN MARY; PAULSEN JANET LEIGH; SCOCCHERA ERIC WILLIAM; VISWANATHAN KISHORE; UNIV CONNECTICUT
    摘要:The compositions and methods described herein disclose the design, synthesis and testing of compounds that act as inhibitors of DHFR. The basic scaffold of these inhibitors includes a 2,4-diaminopyrimidine ring with a propargyl linker to another substituted aryl, bicyclo or heteroaryl ring. These DHFR inhibitors are potent and selective for many different pathogenic organisms, including the DHFR enzyme from bacteria such as Bacillus anthracis and methicillin-resistant Staphylococcus aureus , fungi such as Candida glabrata, Candida albicans and Cryptococcus neoformans and protozoa such as Cryptosporidium hominis and Toxoplasma gondii . These compounds and other similar compounds are also potent against the mammalian enzyme and may be useful as anti-cancer therapeutics.

    专利号:US-8426432-B2
    优先权日:2007-06-04
    标 题 :Inhibitors of dihydrofolate reductase with antibacterial antiprotozoal, antifungal and anticancer properties
    发明人:ANDERSON AMY C; WRIGHT DENNIS L; PELPHREY PHILLIP M; JOSKA TAMMY M; BOLSTAD ERIN S D; BOLSTAD DAVID B; POPOV VELJKO
    权利人:ANDERSON AMY C; WRIGHT DENNIS L; PELPHREY PHILLIP M; JOSKA TAMMY M; BOLSTAD ERIN S D; BOLSTAD DAVID B; POPOV VELJKO; UNIV CONNECTICUT
    摘要:The compositions and methods described herein discloses the design, synthesis and testing of compounds that act as inhibitors of DHFR. The basic scaffold of these inhibitors includes a 2,4-diaminopyrimidine ring with a propargyl linker to another substituted aryl, bicyclo or heteroaryl ring. These DHFR inhibitors are potent and selective for many different pathogenic organisms, including the DHFR enzyme from bacteria such as Bacillus anthracis and methicillin-resistant Staphylococcus aureus , fungi such as Candida glabrata, Candida albicans and Cryptococcus neoformans and protozoa such as Cryptosporidium hominis and Toxoplasma gondii . These compounds and other similar compounds are also potent against the mammalian enzyme and may be useful as anti-cancer therapeutics.

    专利号:CN-118878430-A
    优先权日:2024-08-13
    标 题 :Compound, synthesis method thereof and synthesis method of 5, 6-dihydroxyindole

    专利号:US-2007099880-A1
    优先权日:2003-11-24
    标 题:Estrogen receptor modulators
    发明人:BLIZZARD TIMOTHY A; GUDE CANDIDO; MORGAN JERRY D II
    权利人:BLIZZARD TIMOTHY A; GUDE CANDIDO; MORGAN JERRY D II
    摘要:The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for treatment or prevention of a variety of conditions related to estrogen functioning including: bone loss, bone fractures, osteoporosis, metastatic bone disease, Paget's disease, periodontal disease, cartilage degeneration, endometriosis, uterine fibroid disease, hot flashes, increased levels of LDL cholesterol, cardiovascular disease, impairment of cognitive functioning, cerebral degenerative disorders, restenosis, gynecomastia, vascular smooth muscle cell proliferation, obesity, incontinence, inflammation, inflammatory bowel disease, sexual dysfunction, hypertension, retinal degeneration and cancer, in particular of the breast, uterus and prostate.

    专利号:WO-2025026392-A1
    优先权日:2023-08-02
    标题 :Kinesin kif18a inhibitor and use thereof
    发明人:XIAO YISONG; LAI KUNMIN; GU XIAOHUI; WANG MINGHUA; DENG JIACHEN; HU MIN
    权利人:SHANGHAI APEIRON THERAPEUTICS COMPANY LTD
    摘要:A KIF18 inhibitor having a structure as shown in formula (I) and a synthesis method therefor. The compound can be used to adjust the KIF18A protein, thereby affecting a cell cycle and cell proliferation process for the treatment of cancer and cancer-related diseases. Further disclosed are a pharmaceutical composition containing the compound, and a method for the treatment of conditions associated with KIF18A activity.
    濮阳惠成电子材料股份有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.huichengchem.com
    企业联系电话:19638638286👤
    📞濮阳惠成电子材料股份有限公司 ⚠️参考联系方式
    联系人:张经理
    电话:19638638286
    手机:19638638286
    传真:0393-8961801
    邮箱:info@huichengchem.com
    通信地址: 河南省濮阳市胜利路西段
    邮编: 457001
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    地址:河南省濮阳市胜利路西段
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
    ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    第 1 / 1 页
    现货

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献

    参考标题:Divergent Enantioselective Synthesis Of (−)-Galanthamine And (−)-Morphine
    作者:Barry M. Trost,Weiping Tang,F. Dean Toste |发布日期:2005.10.1
    摘要:Tricyclic Intermediate Is Available In Six Steps From 2-Bromovanillin And The Monoester Of Methyl 6-Hydroxycyclohexene-1-Carboxylate. This Intermediate Requires Only Two Steps To Convert To (-)-Galanthamine. Using A Heck Vinylation, We Found That The Fourth Ring Of Codeine/morphine Could Be Formed. The Final Ring Formation Involves A Novel Visible Light-Promoted Hydroamination. Thus, Six Steps Are Required

    合成参考文献


    摘要:Kleemann, A.; Engel, J.; Kutscher, B.; Reichert, D., Pharmaceutical Substances[Online], Thieme: Stuttgart, (2003).
    摘要:Harcken, C., Science of Synthesis, (2007) 25, 78.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知